Top Suppliers:I want be here
Related CAS#:
99658-03-4 158535-55-8
90880-23-2 34273-12-6
134009-09-9 154040-19-4
332867-16-0 1926163-14-5
581-05-5 799241-26-2
1505357-49-2 1513743-46-8
1513328-73-8 1508693-62-6
1558873-80-5 1509178-53-3
1506600-33-4 1512534-35-8
1531773-94-0 1508859-00-4

99658-03-4

99658-03-4 structure
99658-03-4 structure
  • Name: α-Helical CRF (9-41) trifluoroacetate salt
  • Chemical Name: Corticotropin Releasing Factor Antagonist
  • CAS Number: 99658-03-4
  • Molecular Formula: C166H274N46O53S2
  • Molecular Weight: 3826.36
  • Catalog: Signaling Pathways GPCR/G Protein CRFR
  • Create Date: 2018-12-04 16:25:39
  • Modify Date: 2025-08-21 09:57:48
  • α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo[1][2].
Name Corticotropin Releasing Factor Antagonist
Synonyms MFCD00081543
Description α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo[1][2].
Related Catalog
In Vivo α-Helical Corticotropin Releasing Factor (9-41) (10 μg; the third or lateral ventricle of the brain injection; once) significantly decreases plasma GH values[1]. α-Helical Corticotropin Releasing Factor (9-41) (100 ng/kg; i.c.v. once) affects rhlL-1/β-induced enhancement of the splenic sympathetic activity[2]. Animal Model: Adult Sprague-Dawley rats[1] Dosage: 10 μg Administration: The third or lateral ventricle of the brain injection; 10 μg once Result: Abolished the 10 min electroshocks-produced the decreasing of plasma GH levels by injected into the third or lateral ventricle of the brain 45 min before exposure to stress. Animal Model: Adult Sprague-Dawley rats with immunity of endogenous somatostatin (SS)[1] Dosage: 10 μg Administration: Lateral ventricle brain injection; 10 μg once Result: Showed no effect on plasma GH values in rats whose endogenous SS had been immunoneutralized, but did interfere with the stimulatory effect of GH-releasing factor (GRF). Animal Model: Male Wistar rats with rhlL-1/β injection[2] Dosage: 100 ng/kg Administration: Intracerebroventricularly injection; 100 ng/kg once Result: Completely blocked the rhlL-1/β-induced enhancement of the splenic sympathetic activity, but failed to alter the enhancement of nociceptive behaviors caused by rhlL-1/β.
References

[1]. Rivier C, Vale W. Involvement of corticotropin-releasing factor and somatostatin in stress-induced inhibition of growth hormone secretion in the rat. Endocrinology. 1985 Dec;117(6):2478-82.

[2]. Takakazu Oka, et al. Intracerebroventricular injection of interleukin-1/β induces hyperalgesia in rats. Brain Research, 624 (1993) 61-68.

Density 1.5±0.1 g/cm3
Boiling Point 717.1±60.0 °C at 760 mmHg
Molecular Formula C166H274N46O53S2
Molecular Weight 3826.36
Flash Point 387.5±32.9 °C
Exact Mass 540.075745
LogP 3.33
Vapour Pressure 0.0±2.4 mmHg at 25°C
Index of Refraction 1.602
Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
RIDADR NONH for all modes of transport
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:99658-03-4 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 99658-03-4 | Chemsrc address: https://www.chemsrc.com/en/baike/1466092.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved